Skip to content

Decoding TL1A Blockade: Emerging Therapeutic Strategies for Bridging Critical Gaps in IBD Management
June 15, 2026 | Case Convo w/ Dr. Vipul Jairath
***Post-Survey & Application for CME Credit***

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.Where are you in your career? (Required.)
2.What is your community of practice?(Required.)
3.In your practice, when do you consider and/or offer and/or refer a patient with IBD for a clinical trial assessing the efficacy of a new IBD therapy?(Required.)
4.There are many new exciting MOAs showing promising efficacy in IBD, such as TL1A inhibitors.

In RELIEVE UCCD, a phase 2 induction basket trial, the endoscopic response (>50% reduction from baseline in SES-CD score) at week 14 with Duvakitug 2250mg -> 900mg SQ q2wks vs placebo in mod-severe Crohns was ________(Required.)
EVALUATION FORM
5.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
1. Identify the current unmet clinical needs in IBD management, including remission rates, fibrotic complications, and patient treatment priorities.
2. Explain the pathophysiological mechanisms of the TL1A/DR3 pathway in IBD-associated inflammation and fibrosis.
6.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
The educational resources provided to me at the educational activity are useful to my practice
7.Overall, was this activity fair, balanced and free from commercial bias?
8.If no, please explain:
9.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
10.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
11.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
12.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
13.I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Decoding TL1A Blockade: Emerging Therapeutic Strategies for Bridging Critical Gaps in IBD Management Case Convo" and claim 1.0 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice